Biotech entity

Protagonist Therapeutics

Company PTGX

Protagonist Therapeutics is most often covered alongside Johnson & Johnson, which appears in 2 of these 3 stories. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Each story carries 2 original sources on average, compared with 3.4 for the broader beat in this window.

Last mentioned: Jun 14, 2026

Entity pulse

Recent coverage · Protagonist Therapeutics

3 stories
6 avg impact
33% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 33 percentage points.

  • 33% positive
  • 67% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Protagonist Therapeutics

Protagonist Therapeutics is most often covered alongside Johnson & Johnson, which appears in 2 of these 3 stories. pharma accounts for 2 of the 3 tracked stories, while 1 other category carries the remainder. Each story carries 2 original sources on average, compared with 3.4 for the broader beat in this window. Across a 110-day span, the pace is roughly 0.2 stories per week. Their average consequence score of 6 runs below the beat's 6.1 for that window. Protagonist Therapeutics appears in 3 tracked Biotech stories published from February 25, 2026 through June 14, 2026.

Stories tracked
3
Per week
0.2
Sources per story
2

Computed from the 3 stories linked to this entity, with beat comparisons drawn from all 400 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Protagonist Therapeutics. Shared-story counts are live from our verified record — not editorial picks.

Key Data

ticker
PTGX
name
Protagonist Therapeutics
price
45.2
change
1.2
changePct
2.73

Timeline

  1. Quarterly Earnings

    Expected announcement of financial results and pipeline updates for PTGX and OEZVY.

  2. JNJ-2113 Phase 3 Progress

    Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.

  3. Takeda Partnership

    Protagonist signs a global licensing agreement for rusfertide with $300M upfront.

Stories mentioning Protagonist Therapeutics 3

Pharma Neutral

Protagonist Therapeutics Braces for Q1 Earnings Amid Pipeline Milestones

Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.

2 sources

Protagonist Therapeutics is linked from 3 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.